QBL Short & Long-Term Analysis Dec 17

Here is an update thread to what we're expecting with QBL. Most if not all this data is from the announcements.

• Bauxite
  • MDL granted for South Johnstone
  • the work programme under the MDL has been progressing to plan, and bulk sampling has been undertaken in accordance with the work plan.
  • The granting of the MDL has allowed the company to begin sending bulk samples of bauxite to potential customer refineries in order to secure off take customers for the bauxite ahead of anticipated production next year, and for the purpose of proving the economic and operational feasibility of the entire South Johnstone project with the aim of generating positive net cash flows in the near term under intended Mining Lease (ML) applications
  • A 500g representative bauxite sample was sent to ALS Global for quality control testing and returned results of 30.2% available alumina and 2.8% reactive silica. This grade is very close to the average grade at Camp Creek and representative of the deposit as a whole.
  • Environmental works anticipated to be completed in March 2018. Together these will form the basis of the Company’s mining lease (ML) application which is anticipated to be lodged by the end of April 2018.
• Hemp
  • Vitahemp bulk commercial product launch in January 2018.
  • 20 tonnes of seeds being planted by MCL’s contracted farmers that has been imported this week that should yield in excess of a further 500 tonnes of seed for Vitahemp’s further planned ramped up bulk production in March 2018.
  • "At the moment Vitahemp is working on the orders from last weekend’s highly successful launch, and as the sample range has been quickly snapped up by shareholders, the further larger orders including from the wholesale market, will begin to be filled in the coming weeks"
  • "the board of QBL are pleased to see the Team at Vitahemp meeting its milestones under its business plan"
• Medical marijuana
  • MCL – Vitacann has signed letter of intent for JB subject to full documentation with Israeli recommended group of NA chemists. Sample range of patent pending GMP quality shorted extended release reliving pills. Exclusive market to Australasia.
  • $1M
  • Done in parallel with iCan
  • Further details will be provided once full documentation has been finalised